Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Community Bank N.A.

Community Bank N.A. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,977 shares of the medical research company’s stock after purchasing an additional 391 shares during the period. Community Bank N.A.’s holdings in Thermo Fisher Scientific were worth $2,111,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of TMO. Wedge Capital Management L L P NC boosted its stake in Thermo Fisher Scientific by 8.3% in the 3rd quarter. Wedge Capital Management L L P NC now owns 740 shares of the medical research company’s stock worth $375,000 after purchasing an additional 57 shares in the last quarter. Naples Global Advisors LLC lifted its stake in Thermo Fisher Scientific by 37.3% during the 3rd quarter. Naples Global Advisors LLC now owns 755 shares of the medical research company’s stock valued at $382,000 after acquiring an additional 205 shares during the period. Avior Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 41.2% during the 3rd quarter. Avior Wealth Management LLC now owns 3,812 shares of the medical research company’s stock valued at $1,930,000 after acquiring an additional 1,112 shares during the period. Founders Financial Securities LLC lifted its stake in Thermo Fisher Scientific by 10.5% during the 3rd quarter. Founders Financial Securities LLC now owns 1,669 shares of the medical research company’s stock valued at $845,000 after acquiring an additional 158 shares during the period. Finally, Meridian Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 2.2% during the 3rd quarter. Meridian Wealth Management LLC now owns 2,147 shares of the medical research company’s stock valued at $1,087,000 after acquiring an additional 47 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $3.03 on Wednesday, hitting $577.62. The company had a trading volume of 2,034,882 shares, compared to its average volume of 1,567,231. The company has a market capitalization of $220.48 billion, a PE ratio of 37.39, a PEG ratio of 2.31 and a beta of 0.80. The company’s fifty day moving average price is $572.61 and its 200-day moving average price is $529.06. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the firm earned $5.40 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 over the last 90 days. 0.32% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Royal Bank of Canada lifted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. The Goldman Sachs Group boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Raymond James boosted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.